Carmen Espejo Ruiz I am a senior researcher at the Vall d'Hebron Research Institute since 2014. I develop my research activity in the Clinical Neuroimmunology group – Center d'Esclerosi Múltiple de Catalunya and my main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim to develop new therapeutic strategies. Institutions of which they are part Main researcher Clinical Neuroimmunology Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Carmen Espejo Ruiz LinkedIn Twitter Orcid Institutions of which they are part Main researcher Clinical Neuroimmunology Vall Hebron Institut de Recerca I am a senior researcher at the Vall d'Hebron Research Institute since 2014. I develop my research activity in the Clinical Neuroimmunology group – Center d'Esclerosi Múltiple de Catalunya and my main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim to develop new therapeutic strategies.
I obtained my degree in Biology from the University of Barcelona in 1998. I did my doctoral thesis at the Clinical Neuroimmunology Unit of the Hospital Universitari Vall d'Hebron, in which I studied the role of metallothioneins in the pathogenesis of multiple sclerosis, obtaining my PhD in Biology from the University of Barcelona in 2005. In 2008, I got a Miguel Servet contract that allowed me to establish myself as principal investigator of the Clinical Neuroimmunology group – Multiple Sclerosis Centre of Catalonia. Currently, I am a senior researcher at the Vall d'Hebron Research Institute and develop my scientific activity in the Clinical Neuroimmunology group - Center d'Esclerosi Múltiple de Catalunya. My main scientific interest is the study of the pathogenesis of multiple sclerosis with the aim of developing new therapeutic strategies. I am currently focused on the role of immunosenescence in the pathogenesis of multiple sclerosis and the therapeutic potential of different senolytic drugs. I am also studying how the modification of the gut microbiota, through the administration of probiotics, could constitute a therapeutic tool in multiple sclerosis. Finally, I am carrying out a project that aims to induce immune tolerance, through the use of nanomedicine, with the aim of slowing down the autoimmune response in multiple sclerosis. I have more than 25 years of experience in animal models of multiple sclerosis and in the study of the immune response. At the Vall d'Hebron Research Institute, I am a member (since 2003) and the president (since 2006) of the Animal Experimentation Ethics Committee. I am also part of the Biosafety Committee (since 2015) and the Research Integrity Committee (since 2020). I have participated, as main or collaborating author, in 70 publications indexed in peer review journals. I have supervised eight doctoral theses and eight master's final projects. In addition, I participated as a teacher in various training activities, including the Master of Advanced Immunology at the Autonomous University of Barcelona and the University of Barcelona.
Projects Unitat de Neuroimmunologia Clínica (UNiC) IP: Xavier Montalban Gairín Collaborators: Susana Otero Romero, Carlos Nos Llopis, Sunny Malhotra Sareen, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Carmen Tur Gomez, Jordi Barquinero Mañez, Herena Eixarch Ahufinger, Montserrat Moreno Sánchez, Mar Tintore Subirana, M Jesus Arevalo Navines, Carmen Espejo Ruiz, Angela Vidal Jordana, Joaquin Castillo Justribo, Mireia Castillo Juarez, Nicolás Miguel Fissolo, Georgina Arrambide García Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 43680 Reference: 2009 SGR 793 Duration: 01/01/2010 - 30/04/2014 United Europeans for the development of Pharmacogenomics in Multiple Sclerosis (UEPHA-MS) Grant Agreement Nº 212877 IP: Manuel Comabella Lopez Collaborators: Sunny Malhotra Sareen, Jordi Rio Izquierdo, Xavier Montalban Gairín, Carmen Espejo Ruiz Funding agency: EUROPEAN COMMISSION Funding: 185749.7 Reference: UEPHA-MS_FP7PEOPLE_ITN2008 Duration: 15/09/2008 - 14/09/2012 ¿Participan las proteínas de choque térmico (heat shock protein) en el desarrollo de la Esclerosis Múltiple? IP: Carmen Espejo Ruiz Collaborators: - Funding agency: Fundación Caja Navarra Funding: 760.5 Reference: CAN2008-15272 Duration: 01/01/2009 - 31/12/2009 ¿Podemos retrasar o evitar la neurodegeneración en la Esclerosis Múltiple? IP: Carmen Espejo Ruiz Collaborators: - Funding agency: Fundación Caja Navarra Funding: 15753.98 Reference: CAN2009-16365 Duration: 01/01/2010 - 31/12/2010 Pagination First page « Previous page ‹ … Page 3 Page 4 Current page 5 Page 6 Page 7 Next page › Last page »
